Search Results for 'abstract response'

abstract response published presentations and documents on DocSlides.

ESMO 2022  Congress  Report
ESMO 2022 Congress Report
by paige
NSCLC, . gastric. . cancer. and . other. . soli...
Meeting summary ASCO GU 2020,
Meeting summary ASCO GU 2020,
by patricia
San Francisco. , USA. Assoc. . Prof. . Shilpa Gupt...
A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and
A Phase Ib Dose Escalation Trial of SAR650984 (Anti-CD-38 mAb) in Combination with Lenalidomide and
by scoopulachanel
Myeloma. 1. Safety and Efficacy of Daratumumab wit...
The Impending  D eath of Cancer: A Herculean Task Emerging Therapies 2016
The Impending D eath of Cancer: A Herculean Task Emerging Therapies 2016
by phoebe-click
The Impending D eath of Cancer: A Herculean Task...
Carfilzomib , Rituximab and Dexamethasone (
Carfilzomib , Rituximab and Dexamethasone (
by mindeeli
CaRD. ) Is Highly . Active and . Offers a Neuropat...
Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses
Anti-CD19 Chimeric Antigen Receptor (CAR) T Cells Produce Complete Responses
by chaptoe
with . Acceptable Toxicity . but . w. ithout . Chr...
by billiontins
2018;36(8):773-9.. Nivolumab Monotherapy (Cohort 1...
by thousandnike
actual. . video-recorded proceedings from the . l...
The Impending  D eath of Cancer:
The Impending D eath of Cancer:
by elina
A Herculean Task. Emerging Therapies 2016. Ruemu E...
Is the  acoustic   modality
Is the acoustic modality
by eleanor
. relevant. for . abstract. . concepts. ? An . i...
Please note, these are the actual
Please note, these are the actual
by pinperc
video-recorded proceedings from the . live CME eve...
Highlights in Multiple myeloma
Highlights in Multiple myeloma
by amber
How to treat. triple- or penta-refractory . Multip...
ESMO 2021 (Virtual) Congress Report
ESMO 2021 (Virtual) Congress Report
by SnuggleBug
Lung and gastrointestinal cancers. Slide numbers. ...
 Overall Survival Benefit of
Overall Survival Benefit of
by tatyana-admore
Obinutuzumab. Over Rituximab when Combined with ...
Ezra  W Cohen University of California, San Diego
Ezra W Cohen University of California, San Diego
by natalia-silvester
Ezra W Cohen University of California, San Diego...
Low TPS High TPS TPS = PD-L1 tumor proportion score Low TPS = 10%; high TPS = 60%
Low TPS High TPS TPS = PD-L1 tumor proportion score Low TPS = 10%; high TPS = 60%
by olivia-moreira
Low TPS High TPS TPS = PD-L1 tumor proportion sco...
meeting summary ASH ANNUAL MEETING 2021
meeting summary ASH ANNUAL MEETING 2021
by sophia2
Dr.. Matthew J. . Matasar. , MD. Memorial Sloan K...
 Meet The Professors Hodgkin Lymphoma 2018
Meet The Professors Hodgkin Lymphoma 2018
by conchita-marotz
Hodgkin Lymphoma (HL) by the Numbers. Optimal Upf...
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study
MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study
by chiquity
to . Determine the Maximum Tolerated Dose for the ...
Eribulin   Mesylate  +  Trastuzumab
Eribulin Mesylate + Trastuzumab
by easyho
as First-Line Therapy for Locally Recurrent or . M...
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K
A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K
by windbey
δ. ) Inhibitor, . Idelalisib. (GS-1101) in Combi...
B -Cell Maturation  Antigen (BCMA)-Targeted
B -Cell Maturation Antigen (BCMA)-Targeted
by uoutfeature
Chimeric Antigen Receptor . (CAR) T Cells in Advan...
Servlets (part1) Dr Solange Karsenty
Servlets (part1) Dr Solange Karsenty
by serenemain
Hadassah Academic College. 1. Servlets. ‏. בס�...
Overview of CML & Recent Advances
Overview of CML & Recent Advances
by stella
I. ntroduction. CML is a clonal myeloproliferative...
Abstract Aim We aimed to retrospectively examine thetolerability and
Abstract Aim We aimed to retrospectively examine thetolerability and
by edolie
4231 Correspondence to: Tetsuhiro Chiba, MD, Ph.D....
Cell Therapy Dr. Ronan Foley
Cell Therapy Dr. Ronan Foley
by jade
Insert Photo. Juravinski Cancer Centre. Cell Thera...
meeting summary Autumn 2021 MEETINGS in Multiple Myeloma
meeting summary Autumn 2021 MEETINGS in Multiple Myeloma
by cadie
IMW | SOHO | SOHO Italy. Dr.. Claudio . Cerchione...
MEK Inhibitors and their potential role in relapsed NSCLC
MEK Inhibitors and their potential role in relapsed NSCLC
by debby-jeon
Ranee Mehra, MD. Fox Chase Cancer Center. Philade...
JEJKQNJHKBHHANCUOPDIJIIQJKHKCUWQHAKHQIAOOQA ABSTRACT K
JEJKQNJHKBHHANCUOPDIJIIQJKHKCUWQHAKHQIAOOQA ABSTRACT K
by debby-jeon
ijaaiin DOI 0410309726691124397 Quick Response Cod...
response to avian parasitism, hosts develop a number defenses to reduc
response to avian parasitism, hosts develop a number defenses to reduc
by tawny-fly
ABSTRACT In (Turdus sympatrically and parasite,...
PARCH model is among most popular choices of a discrete time series th
PARCH model is among most popular choices of a discrete time series th
by jane-oiler
Abstract The A - capturing asymmetric responses of...
OHSU Updates in Hematology
OHSU Updates in Hematology
by calandra-battersby
and. Breast Cancer Conference. CML . ASH Update. ...